|
Report No. : |
343130 |
|
Report Date : |
06.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
ZETA PHARM FOR PHARMACEUTICAL INDUSTRIES |
|
|
|
|
Registered Office : |
Rod El Faragel Loaloa Towers, 97 Cornish El Nile, Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Date of Incorporation : |
09.01.2010 |
|
|
|
|
Com. Reg. No.: |
45410, Cairo |
|
|
|
|
Legal Form : |
Egyptian Joint
Stock Company |
|
|
|
|
Line of Business : |
Subject is engaged in the manufacture of pharmaceuticals and medicines |
|
|
|
|
No. of Employee : |
120 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Egypt |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company Name :
ZETA PHARM FOR PHARMACEUTICAL INDUSTRIES
Country of Origin :
Egypt
Legal Form :
Egyptian Joint Stock Company
Registration Date :
9th January 2010
Commercial Registration Number :
45410, Cairo
Tax Card Number :
340-079-975
Issued Capital :
£E 60,000,000
Paid up Capital :
£E 60,000,000
Total Workforce : 120
Activities :
Manufacture of pharmaceuticals and medicines
Financial Condition :
Undetermined
Payments :
Nothing detrimental uncovered
Person Interviewed :
Ahmed Mohamed Ahmed, Accounts & Administration Manager
ZETA PHARM FOR PHARMACEUTICAL INDUSTRIES
Location : Rod El Faragel
Loaloa Towers, 97 Cornish El Nile
Town : Cairo
Country : Egypt
Telephone : (20-2) 24575308
Facsimile : (20-2)
24575308
Mobile : (20-100)
1595789 / 6555009
Email : zetapharm@hotmail.com / info@zetapharm.net
Subject operates from a large suite of offices that are rented and
located in the Central Business Area of Cairo.
Branch Office (s)
Location Description
· 3 Ahmed El Malihi
Street Office
premises
Vini Square
Dokki
Cairo
Tel: (20-2) 237490366 / 237490377
Fax: (20-2) 237490377
· Industrial Area Factory
premises
Sadat City
Name Position
· Yasser Mahmoud Nawar Chairman
· Ibrahim El Desouki Abdul Hamid Vice
Chairman
· Wael Honsy Omar Khalil Managing
Director
· Ahmed Riad Abdul Hamid Director
· Mutawe Salama Mutawe Director
· Dr Ahmed Rajab Shibel Director
· Ahmed Mohamed Ahmed Accounts
& Administration Manager
· Sameh Ghoniam Financial
Manager
· Dr Saeed El Gazzar Sales
Manager
Date of
Establishment : 9th
January 2010
History : Official
production started October 2015, before this manufacture took place in third
party laboratories.
Legal Form : Egyptian Joint
Stock Company
Commercial Reg.
No. : 45410, Cairo
Tax Card No. : 340-079-975
Issued Capital : £E 60,000,000
Paid up Capital : £E 60,000,000
· Yasser Mahmoud Nawar
· Ibrahim El Desouki Abdul Hamid
· Wael Honsy Omar Khalil
· Ahmed Riad Abdul Hamid
· Mutawe Salama Mutawe
· Dr Ahmed Rajab Shibel
· Local businessmen
and private individuals
Activities: Engaged in the manufacture of pharmaceuticals and medicines.
Import Countries: Europe and the Far East
Subject has a workforce of 120 employees.
Companies registered in Egypt are not legally required to make their
accounts public and no financial information was released by the company or
submitted by outside sources.
·
Commercial International Bank (CIB)
Nile Tower Building
21-23 Giza Street
PO Box: 2430
Cairo
Tel: (20-2) 25703043
Fax: (20-2) 25703172 / 25072691
No complaints regarding subject’s payments have been reported.
Local sources report that the subject’s operating history is clear with
payment obligations met in a generally timely manner. The financial position is
satisfactory and the company is deemed a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.29 |
|
|
1 |
Rs.99.31 |
|
Euro |
1 |
Rs.54.39 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.